Ascendiant Capital Markets raised their price objective on shares of Atossa Therapeutics from $7.25 ...
Craig Hallum started coverage on shares of Atossa Therapeutics in a research note on Thursday. They ...
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceut...
Atossa Therapeutics Inc (NASDAQ: ATOS) kicked off on Friday, down -4.39% from the previous trading d...